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Gregory L. Moneta, MD, Section EditorDiscontinuation of Statin in Routine Care Settings: A Cohort Study
Zhang H., Plutzky J., Skentzos S., et al. Ann Intern Med 2013;158:526-34.
Conclusion: Statin-related events occur commonly and often lead to
statin discontinuation. Most patients, however, when rechallenged with sta-
tins, are able to tolerate statins long-term.
Summary: Discontinuation of statin medications has been linked to
an increased risk for cardiovascular events and death in patients with coro-
nary artery disease (Rasmussen JN et al, JAMA 2007;297:177-86). In
reports of statin discontinuation, adverse reactions to statins are featured
prominently. However, in randomized, placebo-controlled, clinical trials,
statins are associated with only a slight increase in adverse reactions over
placebo and with no increase in discontinuation of treatment comparable
with placebo (Sacks FM et al, N Engl J Med 1996;355:1001-9). It is
unclear whether adverse symptomatology attributed to statins will reoccur
when a patient is rechallenged with a different statin or even with the
same statin at a later time. Given the potential adverse effects of statin
discontinuation, the authors sought to investigate reasons for statin discon-
tinuation and the role of statin-related events (clinical events or symptoms
believed to be caused by statins) in routine care settings. This was a retro-
spective cohort study involving patients from the Brigham and Women’s
Hospital and Massachusetts General Hospital in Boston. The study included
adults who received a statin prescription between January 1, 2000, and
December 31, 2008. Information regarding statin discontinuation was ob-
tained from a combination of electronic medical record review and analysis
of electronic provider notes by validated software. There were 107,835
patients identiﬁed as having been treated with statins. Statins were tempo-
rarily discontinued in 57,292 of these patients. In 18,778 (17.4%), statin-
related events were documented as the reason for discontinuation. Of these
patients, statins were discontinued at least temporarily in 11,124 patients,
and 6579 were rechallenged with a statin in the subsequent 12 months.
Most patients who were rechallenged (92.2%) were still taking a statin 12
months after the statin-related event. Of 2721 patients who were rechal-
lenged with the same statin to which they had a statin-related event,
1295 continued to receive that same statin 8 months later. In fact, 996
were receiving the same dose or a higher dose.
Comment: Events attributed to statins are common. However, the
data suggest most patients when rechallenged with statins can tolerate
them long-term, including patients rechallenged with the same statin that
led to their statin-related event! Perhaps statin-related events have other
causes than the medication itself, or are more tolerable, or more speciﬁc
to individual drugs than previously appreciated. At the very least, it seems
patients who are discontinued from statin medications deserve an attempt
to retry the same drug at a different dose or to be rechallenged with
a different statin.
Asymptomatic Carotid Artery Stenosis and the Risk of Ischemic Stroke
According to Subtype in Patients With Clinical Manifest Arterial
Disease
den Hartog A.G., Achterberg S., et al; the SMART Study Group. Stroke
2013;44:1002-7.
Conclusion: Patients with clinical arterial disease or type 2 diabetes
have a low risk of developing ischemic stroke, irrespective of subtype and
independent of the degree of asymptomatic carotid artery stenosis (ACAS).
Summary: In the general population, between 0% and 7.5% of asymp-
tomatic patients have $50% ACAS and between 0% and 3.1% have >70%
ACAS (de Weerd M et al, Stroke 2010;41:1294-7). A recent study of
patients with $50% ACAS and contralateral transient ischemic attacks or
stroke, who were on intensive medical therapy, demonstrated the average
annual risk of ipsilateral stroke or transient ischemic attack was 0.34%
(95% conﬁdence interval, 0.01-1.87; Marquardt L et al, Stroke
2010;41:e11-7). In this paper, the authors report their observations on
the development of ischemic stroke in patients with ACAS. This is
a secondary analysis of the Second Manifestations of Arterial Disease
(SMART) study. The SMART study is a single-center prospective cohort
study among patients referred to the University Medical Center in Utrecht
who have clinically manifest atherosclerotic disease or have risk factors for
atherosclerosis (Simons PC et al, Eur J Epidemiol 1999;15:773-81).
Patients in SMART are aged 18 to 79 years and initially undergo a standard-
ized vascular screening at baseline that includes a health questionnaire,laboratory assessment, and duplex ultrasound (DUS) imaging to investigate
for the prevalence of vascular disease. The patients are then followed up
prospectively. There are a total of 5866 SMART patients. Of these, 1473
had a history of cerebrovascular disease before their inclusion in SMART
or had missing DUS data. This left 4319 patients available for analysis in
this paper. No patient in the current analysis had a history of symptomatic
cerebrovascular disease. Carotid stenosis was evaluated with DUS imaging,
and strokes were classiﬁed during follow-up according to subtype as large
vessel or small vessel. Cox proportional hazard regression models were
used to evaluate the relationship between ACAS and future stroke. ACS
of 50% to 99% was present in 293 patients (6.8%), and of these, 193 had
70% to 99% ACAS. In these two subgroups, mean follow-up was 6.2 and
6.0 years, respectively. A total of 94 ischemic strokes occurred, eight of
which were in the 50% to 99% ACAS patients. The any-territory annual
ischemic stroke risk was 0.4% in 50% to 99% ACAS patients and 0.5% for
79% to 99% ACAS patients. Risk of ischemic stroke was not increased in
patients with 70% to 99% ACAS (hazard ratio [HR], 1.5; 95% conﬁdence
interval [CI], 0.7-3.5). There tended to be nonsigniﬁcantly more large-
vessel strokes in patients with 50% to 99% ACAS (HR, 1.5; 95% CI, 0.5-
4.2) than in patients with 70% to 99% ACAS (HR, 1.7; 95% CI, 0.5-5.6).
Comment: This is a strong study. The data were collected prospec-
tively, included a large number of patients, and patients were censored after
undergoing a carotid intervention. Follow-up was also longer compared
with much of the existing literature. The data appear concordant with the
emerging position that the natural history of ACAS with current medical
management is better than it used to be. The result is that interventions
for ACAS are coming under increasing question. The authors argue “for
a conservative approach in ACAS in general and revascularization only
within the conﬁnes of well-designed randomized clinical trials.”
n-3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
The Risk and Prevention Study Collaborative Group. N Engl J Med
2013;368:1800-8.
Conclusion: In patients with multiple cardiovascular risk factors, daily
treatment with n-3 fatty acids does not reduce cardiovascular mortality or
morbidity.
Summary: It has been suggested that n-3 polyunsaturated fatty acids
derived from ﬁsh reduce the risk of cardiovascular disease through beneﬁcial
effects on arrhythmias and atherosclerotic, inﬂammatory, and thrombotic
processes (De Caterina R, N Engl J Med 2011;364:2439-50). Indeed,
beneﬁt of n-3 fatty acids has been demonstrated to reduce cardiovascular
mortality and morbidity in patients surviving myocardial infarction and in
patients with heart failure (Lancet 1999;354:447-55 and Lancet
2008;372:1223-30). The current study, the Risk and Prevention Study,
was a double-blind, placebo-controlled trial to assess the efﬁcacy of n-3 fatty
acids in patients with multiple cardiovascular risk factors or atherosclerotic
vascular disease, but not myocardial infarction. Patients were chosen and fol-
lowed up by a network of 860 general practitioners in Italy and randomly
assigned to n-3 fatty acids (1 g daily) or placebo (olive oil). The prespeciﬁed
end point initially for the study was the cumulative rate of death, nonfatal
myocardial infarction, and nonfatal stroke. At 1 year, the event rate was
lower than anticipated; therefore, the primary end point was revised to
time to death from cardiovascular causes or admission to the hospital for
cardiovascular causes. The study enrolled 12,513 patients, and 6244 of
these were randomly assigned to n-3 fatty acids and 6269 to placebo.
Median follow-up was 5 years. The primary end point occurred in 1478
of the 12,505 patients included in the analysis. Of these, 733 of 6239
(11.7%) had received n-3 fatty acids and 745 of 6266 (11.9%) had received
placebo. The adjusted hazard ratio with n-3 fatty acids was 0.97 (95% conﬁ-
dence interval, 0.88-1.08; P ¼ .58). The same results were also observed for
secondary end points.
Comment: Fish oil appears to be joining an ever-expanding list of inef-
fective, but popular and well publicized, therapies for primary prevention of
cardiovascular disease. Consistent negative ﬁndings across the study prohibit
much in the way of alternative explanations for the data. However, the lower
event rate than expected, combined with the dietary habits of the Italian pop-
ulation and intensive exposure to other preventive treatments during the 5-
year follow-up period, may have inﬂuenced the results. It is also important
to note that these results do not negate the previously determined beneﬁts843
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failure. The authors suggest primary beneﬁt of n-3 fatty acids is antiar-
rhythmic in patients, such as those with previous myocardial infarction or
heart failure, who are perhaps more prone to ventricular arrhythmic events.
Malignant Emboli on Transcranial Doppler During Carotid Stenting
Predict Postprocedure Diffusion-Weighted Imaging Lesions
Almekhlaﬁ M.A., Demchuk A.M., Mishra S., et al. Stroke 2013;44:1317-
22.
Conclusion: There is a high incidence of embolic signals during
carotid artery stenting, especially when devices are deployed. Malignant
macroemboli predict new images on diffusion-weighted magnetic resonance
imaging (MRI).
Summary: It is now clear that carotid angioplasty and stenting (CAS)
procedures have an increased risk of periprocedural stroke compared with
endarterectomy (Yavin D et al, Can J Neurol Sci 2011;38:230-5). Up to
50% of patients undergoing CAS will have new ischemic lesions on MRI
of the brain after the procedure (Bonati LH et al, Lancet Neurol
2010;9:353-62). The authors postulate that investigating the relative safety
of each step of CAS may help guide improvements in the procedure to lower
the periprocedural stroke rate. They therefore investigated the relative safety
of the steps of CAS by performing intraprocedural transcranial Doppler
(TCD) monitoring and correlating TCD ﬁndings with diffusion-weighted
MRI after the procedure. This was a prospective study in which TCD moni-
toring was performed during CAS procedures. For purposes of the study,
CAS was divided into 11 procedural steps. Embolic signals on TCD were
counted and classiﬁed based on the relative energy index of microembolic
signals as microemboli of one or less or malignant macroemboli as more
than one. All patients had poststenting MRI. The predictive value of
TCD-detected emboli for new diffusion-weighted imaging (DWI) lesions
was evaluated with a negative binomial regression model. The study
enrolled 30 patients, and seven were asymptomatic. The median embolic
signal count was 212.5 (108 microemboli and 80 malignant macroemboli).
The highest median embolic signals occurred during stent deployment, with
a signal count of 58. This was followed by protection device deployment
with a signal count of 30 (P ¼ .0006). Twenty-four patients (80%) had
new DWI lesions on post-CAS MRI. The median DWI count was four
(interquartile range, seven). Two patients (6.7%) had new or worsening
clinical deﬁcits post-CAS. For every malignant embolus, the expected count
of DWI lesions increased by 1% (95% conﬁdence interval, 0%-2%; P ¼ .032).
Comment: It is not surprising that deploying the protection device
and deploying the stent would be associated with the greatest number of
TCD-detected emboli. Fig 2 of the article, however, indicates that all phases
of CAS are associated with TCD-detected microemboli and malignant mac-
roemboli. Although it is true that identifying particular procedural steps that
contribute to improving the adverse event rates of CAS may be important in
improving the procedure, it is also possible CAS is a failed concept for most
patients and should be relegated to very speciﬁc and highly individualized
clinical indications.
Outcomes of Carotid Endarterectomy in the Elderly: Report From the
National Cardiovascular Data Registry
Rajamani K., Kennedy K.F., Ruggiero N.J., et al. Stroke 2013;44:1172-4.
Conclusion: For patients undergoing carotid endarterectomy (CEA),
those aged >85 years are at increased risk for death or perioperative compli-
cations of stroke, death, and myocardial infarction (MI) compared with
younger patients.
Summary: There are case series of CEA that suggest the perioperative
risk in elderly patients is comparable with that in younger patients (Durward
QJ et al, Arch Surg 2005;140:625-8). However, administrative databases
and systemic reviews have suggested CEA in the elderly patient has
increased perioperative morbidity and mortality (Wennberg DE et al,
JAMA 1998;279:1278-81 and Bond R et al, Cerebrovasc Dis
2005;20:69-77). In this paper, the authors, who all appear to be cardi-
ology-based or have connections with the carotid stent industry, report
the result of the CARE registry with respect to CEA in older patients.
The CARE registry is a voluntary, hospital-based, prospective, clinical
procedures registry (https://www.ncdr.com/webncdr/care/; White CJ
et al, Catheter Cardiovasc Interv 2008;71:721-5). The authors believe
that analysis of data from the CARE registry helps to determine “real-
world” outcomes of CEA in the elderly. This was a retrospective cohort
study of patients aged >70 years. Outcomes were stratiﬁed by age and
symptomatic and asymptomatic status. The registry includes data from
171 hospitals, and 4149 patients underwent CEA, 33.1% of whom were
symptomatic. Overall mortality rate was 0.5%. The primary outcome
measure of in-hospital death, stroke, and myocardial infarction was highest
in the group aged >85 years (5.6%). Among symptomatic patients,mortality and the primary outcome were not statistically different between
those aged >75 years and those aged 70 to 74 years. Among asymptomatic
elderly patients, the mortality rate was higher in aged patients >75 years
than in those <75 years (0.7% vs 0.0%, P ¼ .006). However, the combined
outcome of stroke, death, and myocardial infarction was not statistically
different.
Comment: It is a little hard to know what to make of these data.
There were 4149 patients analyzed from January 2005 to March 2011,
purportedly from 171 hospitals. This roughly equates to w25 CEAs, on
average, from each hospital. Over 6 years, this would be less than ﬁve
CEAs per year in each of these hospitals in patients aged >70 years. Either
a lot of potential data are not being analyzed or these are very low-volume
CEA hospitals. Therefore, although enough numbers are here to do statis-
tical analysis, it is very unclear whether the patients analyzed are truly repre-
sentative of those undergoing CEA across the United States. Nevertheless,
likely at the disappointment of the authors, the overall perioperative risk of
complications after CEA in the elderly analyzed within this registry was still
within guidelines for CEA.
Prevalence of Stenoses and Occlusions of Brain-Supplying Arteries in
Young Stroke Patients
von Sarnowski B., Schminke U., Tatlisumak T., et al. Neurology 2013;80:
1287-94.
Conclusion: One-ﬁfth of young patients with stroke have asymptom-
atic or symptomatic large-artery atherosclerosis.
Summary: Signiﬁcant extracranial atherosclerotic carotid stenosis and
occlusions in adult stroke patients of all ages (21-94 years old) occur in 11%
to 22% (Bogousslavsky J et al, Stroke 1988;19:1083-92 and Wasay M et al,
Stroke 2009;40:708-12). However, in younger patients with stroke, athero-
sclerotic changes in the extracranial and large intracranial arteries have not
been considered a major etiology of stroke. Only two previous studies
have reported the prevalence of atherosclerotic stenosis in young stroke
patients, with prevalence of stenosis ranging from 8% to 13% and a 3% prev-
alence of occlusions in transient ischemic attack (TIA) and ischemic stroke in
patients aged<45 years (Carolei A et al, BMJ 1995;310:1363-6 and Lee TH
et al. Stroke 2002;33:1950-5). The authors here aimed to assess the preva-
lence of extracranial and intracranial atherosclerotic stenotic lesions and
occlusions in TIA and ischemic stroke patients aged 18 to 55 years in the
large European, multicenter database of the Stroke in Young Fabry Patients
(Sifap1) study. Sifap1 is a Pan-European multicenter study conducted in 47
centers in 15 countries. The study is primarily designed to investigate the
prevalence of Fabry disease. The current study is a secondary analysis of Sifap
1 data. From the Sifap 1 cohort (n ¼ 5023), the authors analyzed a subset of
patients with complete data from carotid ultrasound studies. Patients with
arterial dissections, vasculitis, and mobile thrombi were excluded. Among
the remaining 2187 patients (1319 men; 744 aged 18-44 years), intracranial
arteries were additionally examined with ultrasound imaging in 1612
patients (73.7%). Patients were stratiﬁed by sex and age groups (younger:
18-44 years; middle-aged: 45-55 years). In patients with ischemic stroke,
overall prevalence of carotid artery stenosis and occlusions was 8.9%
(younger: 4.9%; middle-aged: 11.0%), of which 81% were symptomatic.
Nonstenotic carotid plaques were more common in men than in women
(15.8% vs 7.7%; P < .001) and in middle-aged rather than in younger
patients (17.0% vs 4.9%; P< .001). Supratentorial intracranial artery stenosis
and occlusions amounted to 11.8%. Supratentorial stenosis occurred more
frequently in middle-aged patients (13.0% vs 7.8%; P< .001), whereas occlu-
sions were equally common (both 3.2%; not signiﬁcant).
Comment: The study did not include a control population without
TIA or stroke. The cross-sectional study design does not allow assessment
of the role of progressive atherosclerotic stenosis in the etiology of stroke
in young patients. The study does, however, indicate a high burden of
subclinical atherosclerosis in middle-aged TIA and stroke patients. Of
ischemic stroke patients aged 45 to 55 years, 17% have a detectible carotid
plaque. The study also indicates that intracranial stenosis occurs with reason-
able frequency in young patients with stroke. This suggests that in addition
to carotid duplex scanning to access for cervical carotid lesions, imaging of
intracranial arteries should also be considered in the young stroke patient.
Risk Factors for Early Failure of Surgical Amputations: An Analysis of
8,878 Isolated Lower Extremity Amputation Procedures
O’Brien P.J., Cox M.W., Shortell C.K., et al. J Am Col Surg 2013;216:
836-44.
Conclusion: The risk of early amputation failure can be decreased by
increased operative times and heightened supervision of participating
surgical trainees.
Summary: Nearly 100,000 lower extremity amputation procedures
are performed in the United States each year for complications of critical
